CoreValve is a pioneering company focused on advancing non-surgical aortic heart valve replacement technology. Founded in 2001 by cardiac surgeon Jacques Seguin, M.D., Ph.D., the company has made significant strides in developing and implementing catheter-based aortic valve replacement procedures. With over 200 patients successfully treated using the CoreValve ReValving™ procedure, the company has demonstrated the practical application of its breakthrough technology.
CoreValve's vision encompasses leadership in technology, clinical practice, and market presence in percutaneous heart valve replacement therapies. While the current emphasis is on percutaneous aortic valve replacement, future endeavors will focus on developing minimally invasive treatments for structural heart diseases. Notably, the company is headquartered in Irvine, California, strategically positioning itself in a vibrant hub for innovative heart valve technology advancements.
The latest significant milestone for CoreValve was a $33.00M Series C investment on 28 March 2007, secured from prominent investors including Sofinnova Partners, Apax Partners, HealthCap, and Maverick Global Ventures.
